Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

Abstract

The efficacy and safety of the preprandial injection of insulin lispro was compared with the oral administration of glibenclamide in patients with early type 2 diabetes. In this open-label, multicenter study, 143 patients with a glucagon-stimulated increase in C-peptide of at least 0.4 nmol/L were randomized to receive preprandial insulin lispro (LP) or glibenclamide (GB) for 26 weeks. Seventy-five patients received LP (51 male/24 female; age 40 to 70 years, duration of diabetes 4.4 ± 2.9 years) and 68 patients received GB (39 male/29 female; age 39 to 70 years; duration of diabetes 4.3 ± 3.4 years). After 12 weeks, mean 90 minute blood glucose excursions were 0.9 ± 1.0 mmol/L for LP and 1.8 ± 1.2 mmol/L for GB (p < 0.0001). After 24 weeks, mean blood glucose excursions were 1.0 ± 1.1 mmol/L for LP and 1.7 ± 1.2 mmol/L for GB (p = 0.002). Body weight decreased slightly from 87.2 ± 2.3 to 86.5 ± 12.2 kg in the LP group and increased from 84.1 ± 13.7 to 84.4 ± 13.3 kg in the GB group. LP versus GB induced changes from baseline to endpoint in fasting C-peptide (nmol/L), proinsulin and insulin levels (pmol/L) were - 0.2 ± 0.4 versus - 0.1 ± 0.6 (p = 0.04), - 11.2 ± 26.0 versus - 1.1 ± 17.3 (p = 0.03), and - 27.8 ± 147.4 versus + 32.6 ± 286.2 (not significant), respectively. HbA_1c at baseline was 7.5 ± 1.0 % for LP and 7.7 ± 1.2 % for GB and did not change significantly in either group during the investigation. No significant difference was observed between the groups with respect to hypoglycemic episodes. Treatment with LP improved postprandial blood glucose control more than GB without increasing body weight or hypoglycemic episodes. In addition, use of LP was associated with a decrease in fasting C-peptide and proinsulin levels, suggesting a potential down regulation of endogenous insulin production and improved proinsulin processing efficiency.

Early diabetes type 2 - Insulin lispro - Glibenclamide - C-peptide - Proinsulin - HbA_1c

References

• 1 Agardh C D, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus.  Diabetes Care. 1982;  5 322-325
• 2 Andrews W J, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven G M. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.  Diabetes. 1984;  33 634-642
• 3 Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer A F. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro.  Diabetologia. 2001;  44 188-195
• 4 Ayo S H, Radnik R, Garoni J A, Troyer D A, Kreisberg J I. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures.  Am J Physiol. 1991;  261 F571-F577
• 5 Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study.  Diabetes Care. 1998;  21 1236-1239
• 6 Bastyr III E J, Johnson M E, Trautmann M E, Anderson Jr. J H. Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.  Clin Ther. 1999;  21 1703-1714
• 7 Bowsher R R, Wolny J D, Frank B H. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum.  Diabetes. 1992;  41 1084-1090
• 8 Bruce D G, Chisholm D J, Storlien L H, Borkman M, Kraegen E W. Meal-time intranasal insulin delivery in type 2 diabetes.  Diabet Med. 1991;  8 366-370
• 9 Bruce D G, Chisholm D J, Storlien L H, Kraegen E W. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes.  Diabetes. 1988;  37 736-744
• 10 Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M C, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.  Diabetes. 1999;  48 99-105
• 11 Calles-Escandon J, Robbins D C. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose.  Diabetes. 1987;  36 1167-1172
• 12 Ceriello A. Acute hyperglycaemia and oxidative stress generation.  Diabet Med. 1997;  14 (Suppl 3) S45-S49
• 13 Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress.  Metabolism. 1996 a;  45 498-501
• 14 Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress.  Diabetes. 1995;  44 924-928
• 15 Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.  Diabetologia. 1996 b;  39 469-473
• 16 de Vegt F, Dekker J M, Ruhe H G, Stehouwer C D, Nijpels G, Bouter L M, Heine R J. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study.  Diabetologia. 1999;  42 926-931
• 17 DeFronzo R A. The effect of insulin on renal sodium metabolism. A review with clinical implications.  Diabetologia. 1981;  21 165-171
• 18 Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.  Diabetes Metab Res Rev. 2001;  17 164-174
• 19 Feinglos M N, Thacker C H, English J, Bethel M A, Lane J D. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.  Diabetes Care. 1997;  20 1539-1542
• 20 Garvey W T, Olefsky J M, Griffin J, Hamman R F, Kolterman O G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.  Diabetes. 1985;  34 222-234
• 21 Gerich J E. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?.  Diabetes. 2002;  51 (Suppl 1) S117-S121
• 22 Hanefeld M, Fischer S, Julius S, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up.  Diabetologia. 1996;  39 1577-1583
• 23 Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.  Atherosclerosis. 1999;  144 229-235
• 24 Hanley A J, McKeown-Eyssen G, Harris S B, Hegele R A, Wolever T M, Kwan J, Connelly P W, Zinman B. Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition.  Diabetes Care. 2001;  24 1240-1247
• 25 Heinemann L, Heise T, Wahl L C, Trautmann M E, Ampudia J, Starke A A, Berger M. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.  Diabet Med. 1996;  13 625-629
• 26 Hosker J P, Burnett M A, Matthews D R, Turner R C. Suppression of insulin secretion by falling plasma glucose levels is impaired in type 2 diabetes.  Diabet Med. 1988;  5 856-860
• 27 Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro(B29)]-human insulin.  Diabetes. 1994;  43 396-402
• 28 Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Care. 1997;  20 1353-1356
• 29 Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.  Diabet Med. 1993;  10 27-32
• 30 Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.  Diabetes Care. 1989;  12 680-685
• 31 Kraegen E W, Young J D, George E P, Lazarus L. Oscillations in blood glucose and insulin after oral glucose.  Horm Metab Res. 1972;  4 409-413
• 32 Lefebvre P, Scheen A J. The postprandial state and risk of cardiovascular disease.  Diabet Med. 1998;  15 S63-S68
• 33 Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?.  Diabetologia. 1996;  39 503-514
• 34 Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.  BMJ. 1997;  314 1512-1515
• 35 Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.  Eur Heart J. 1996;  17 1337-1344
• 36 Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.  Diabetes. 1990;  39 1381-1390
• 37 Muhlhauser I, Sawicki P T, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.  Diabetologia. 1997;  40 1492-1493
• 38 Nagi D K, Hendra T J, Ryle A J, Cooper T M, Temple R C, Clark P M, Schneider A E, Hales C N, Yudkin J S. The relationships of concentrations of insulin, intact proinsulin and 32 - 33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects [see comments].  Diabetologia. 1990;  33 532-537
• 39 Owens D R, Jones M K, Hayes T M, Heding L G, Alberti K G, Home P D, Burrin J M. Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin.  Lancet. 1981;  2 118-122
• 40 Panahloo A, Mohamed-Ali V, Andres C, Denver A E, Yudkin J S. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.  Metabolism. 1998;  47 637-643
• 41 Paterson K R, Wilson M, Kesson C M, Buchan M, Roberts M, Reith S B, Davidson E. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.  Diabet Med. 1991;  8 40-43
• 42 Poitout V, Robertson R P. An integrated view of beta-cell dysfunction in type-II diabetes.  Annu Rev Med. 1996;  47 69-83
• 43 Polonsky K S. Non-insulin dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance.  N Engl J Med. 1996;  334 777-783
• 44 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 45 Robbins D C, Jaspan J, Vasquez B, Van Cauter E. Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects.  Diabetes Care. 1987;  10 293-299
• 46 Shaw J E, Hodge A M, de Courten M, Chitson P, Zimmet P Z. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality [published erratum appears in Diabetologia 1999; 42: 1444].  Diabetologia. 1999;  42 1050-1054
• 47 Temelkova-Kurktschiev T S, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, Hanefeld M. Increased intima-medial thickness in newly detected type 2 diabetes: risk factors.  Diabetes Care. 1999;  22 333-338
• 48 Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose.  Diabetes Care. 1999;  22 920-924
• 49 Torlone E, Fanelli C, Rambotti A M, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM.  Diabetologia. 1994;  37 713-720
• 50 Turner R C, McCarthy S T, Holman R R, Harris E. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.  Br Med J. 1976;  1 1252-1254
• 51 Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus.  Diabetologia. 1988;  31 355-360
• 52 Yudkin J S. Circulating proinsulin-like molecules.  J Diabetes Complications. 1993;  7 113-123
• 53 Yudkin J S, May M, Elwood P, Yarnell J W, Greenwood R, Davey S G. Concentrations of proinsulin-like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study.  Diabetologia. 2002;  45 327-336